These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17461210)

  • 1. [T-PA].
    Takada T; Minematsu K
    Nihon Rinsho; 2006 Oct; 64 Suppl 7():585-8. PubMed ID: 17461210
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thrombolytic treatment in acute brain infarction].
    Davalos A
    Neurologia; 2004 May; 19(4):143-5. PubMed ID: 15131732
    [No Abstract]   [Full Text] [Related]  

  • 3. Administration of recombinant tissue plasminogen activator to a case of cerebral infarction in the setting of painless aortic dissection.
    Takeuchi S; Takasato Y; Masaoka H; Otani N
    Neurol India; 2009; 57(6):808-9. PubMed ID: 20139520
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pleiotropic effects of tissue plasminogen activator].
    Itoh Y
    Nihon Rinsho; 2006 Oct; 64 Suppl 7():589-96. PubMed ID: 17465065
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fibrinolytic therapy in ischemic brain infarct].
    Del Zoppo GJ; Hacke W
    Dtsch Med Wochenschr; 1987 Apr; 112(15):603-8. PubMed ID: 3104001
    [No Abstract]   [Full Text] [Related]  

  • 6. [Quick diagnostic neuroimaging for acute cerebral infarction and decision-making on thrombolytic therapy].
    Nakagawara J
    Nihon Rinsho; 2006 Nov; 64 Suppl 8():25-8. PubMed ID: 17471624
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thrombolytic therapy in acute ischemic stroke: present and future].
    Mori E
    No Shinkei Geka; 2003 Mar; 31(3):249-60. PubMed ID: 12684978
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
    Jin L; Jin H; Zhang G; Xu G
    Clin Hemorheol Microcirc; 2000; 23(2-4):213-8. PubMed ID: 11321442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombolytic therapy of cerebral infarction using alteplase--the Helsinki model].
    Lindsberg PJ; Soinne L; Roine RO; Salonen O; Tatlisumak T; Kallela M; Häppölä O; Tiainen M; Haapaniemi E; Kuisma M; Kaste M
    Duodecim; 2003; 119(18):1723-9. PubMed ID: 14587458
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects].
    Samama M; Verdy E; Conard J; Vahanian A; Michel P; Van Dreden P; Nguyen G; Horellou MH; Combrisson A; Acar J
    Arch Mal Coeur Vaiss; 1986 Oct; 79(11):1618-24. PubMed ID: 3103572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of lesion side on acute stroke treatment.
    Di Legge S; Fang J; Saposnik G; Hachinski V
    Neurology; 2005 Jul; 65(1):81-6. PubMed ID: 16009890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator (t-PA). Will it fulfill its promise?
    Sherry S
    N Engl J Med; 1985 Oct; 313(16):1014-7. PubMed ID: 3930959
    [No Abstract]   [Full Text] [Related]  

  • 14. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 15. [Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice].
    Feuerhake W; Chamorro H; Araya F
    Rev Med Chil; 1999 Jul; 127(7):814-9. PubMed ID: 10668289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model.
    Suzuki M; Sasamata M; Miyata K
    Brain Res; 2003 Jan; 959(1):169-72. PubMed ID: 12480171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary angioplasty or t-PA for the management of acute myocardial infarction?
    Bailey G; Flynn CA
    J Fam Pract; 1999 Aug; 48(8):577-8. PubMed ID: 10496629
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue-type plasminogen activator: a new fibrinolytic agent.
    Milligan KS
    Heart Lung; 1987 Jan; 16(1):69-74. PubMed ID: 3098703
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Relationship Between Peripheral Red Cell Distribution Width and Acute Cerebral Infarction in Patients with rtPA Thrombolysis.
    Cong L; Gao H; Ma W
    Neurotox Res; 2020 Jun; 38(1):211-218. PubMed ID: 32162280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.